COMP <GO>
GMED vs GKOS // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Globus Medical Inc. (NYSE) VS. Glaukos Corporation (NYSE) • 15-METRIC TALLY: GMED 8
— GKOS 4
■ METRIC PARITY
LAST: $78.05 (-5.86%) • MKT CAP: $10.48B
options-implied-move
—
LAST: $237.60 (-2.01%) • MKT CAP: $14.07B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMED VS. GKOS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMED | GKOS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.40% | 55.70% | +11.70 | GMED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | -13.70% | +22.40 | GMED | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.29% | -0.16% | +5.45 | GMED | /fcf-yield <GO> |
| Operating Margin | 16.30% | -39.30% | +55.60 | GMED | /operating-margins <GO> |
| Net Profit Margin | 18.30% | -37.00% | +55.30 | GMED | /net-margins <GO> |
| Revenue Growth (YoY) | 16.70% | 32.30% | -15.60 | GKOS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.74 | 26.00 | -15.26 | GKOS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | GMED | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 78.7 | -30.70 | GKOS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.04 | +0.03 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 34.0x | -16.60 | GMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.48B | $14.07B | -$3.59B | GKOS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMED REV | GKOS REV | GMED GROSS % | GKOS GROSS % | GMED FCF | GKOS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | $507.4M | 67.4% | 55.7% | $588.8M | -$22.5M |
| FY 2024 | $2.52B | $383.5M | 58.9% | 75.5% | $405.2M | -$67.6M |
| FY 2023 | $1.57B | $314.7M | — | — | $172.9M | -$71.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMED // BETA 1.07
GKOS // BETA 1.04